Ray Harrison has a genetic & business degree. Previously he worked for Thorn-EMI in scientific instrumentation. At McCann Erickson, in NYC, he worked biotech analysis and business development for many biotech businesses located the UK, US and Europe. He has raised £30m for US biotechs with European pharmaceutical & diagnostic corporations. He founded the genetic basis of Sciona, a company that went on to raise $10m with Burrell & Co, in Colorado

Andy Allars is a biochemist and established the biotech portfolio of Prelude Investments a Cambridge Seed Venture Capital company now owned by Espirit ZBD. Andy has placed 4 biotech companies on the LSE. He has vast experience in this field and is a potential Chairman and not yet joined the Company.

Dr Matthew Pocock
Matthew took an undergraduate degree in genetics from Newcastle University and PhD jointly with Darwin College, Cambridge and the Sanger Centure, Hinxton, developing software platforms for the human genome project. Matthew's academic interests include software architecture, distributed computing, evolutionary computing, evolutionary biology, data integration, ontologies, and modeling of biological systems.

Professor Sebastian Amyes was professor of microbiology at Edinburgh University. Sebastian is a world authority on the β-lactamases. These enzyme groups were identified and sequenced by him in multi million £ projects, under his stewardship. He classified β-lactamases establishing the international convention of the field, with 500 publications. He has advised several pharmaceutical companies and a VC backed antibiotics company.